Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
The receipt of this order further strengthens the company's position in the global pharmaceutical market
_256_384.jpg)
The hospital has already onboarded 200+ experienced doctors and is expected to generate 5,000–7,000 jobs
The study, which enrolled 35 Japanese patients, evaluated the percent change from baseline in the 24-hour urine protein-to-creatinine ratio
Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division
Subscribe To Our Newsletter & Stay Updated
